Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Gaballa S, et al. Among authors: brammer je. Cancer. 2016 Nov 15;122(21):3316-3326. doi: 10.1002/cncr.30180. Epub 2016 Jul 12. Cancer. 2016. PMID: 27404668 Free PMC article. Clinical Trial.
Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms.
Isabelle C, Johnson WT, McConnell K, Vogel A, Brammer JE, Boles A, Keller R, Sindaco P, Nisenfeld L, Uppal G, Nikbakht N, Calabretta B, Porazzi P, Gong J, Chakravarti N, Porcu P, Mishra A. Isabelle C, et al. Among authors: brammer je. Blood Adv. 2023 Jul 25;7(14):3637-3641. doi: 10.1182/bloodadvances.2023009807. Blood Adv. 2023. PMID: 36989058 Free PMC article. No abstract available.
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Haverkos B, et al. Among authors: brammer je. Blood Adv. 2023 Oct 24;7(20):6339-6350. doi: 10.1182/bloodadvances.2023010330. Blood Adv. 2023. PMID: 37530631 Free PMC article. Clinical Trial.
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Alousi AM, et al. Among authors: brammer je. Biol Blood Marrow Transplant. 2015 May;21(5):906-12. doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7. Biol Blood Marrow Transplant. 2015. PMID: 25667989 Free PMC article. Clinical Trial.
69 results